Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

927
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
927
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

647
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
647
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

752
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
752
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

1.2K
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting neutrophil serine proteases in bronchiectasis.

The European respiratory journal·2024
Same author

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.

The Lancet. Respiratory medicine·2024
Same author

Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.

The European respiratory journal·2024
Same author

Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients.

American journal of respiratory and critical care medicine·2024
Same author

The 6th World Bronchiectasis and Nontuberculous Mycobacteria Conference Abstract Presentations.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2023
Same author

A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf.

ERJ open research·2023

Related Experiment Video

Updated: Apr 16, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

34.3K

Bronchiectasis: which antibiotics to use and when?

Anne E O'Donnell1

  • 1Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center, Washington, DC, USA.

Current Opinion in Pulmonary Medicine
|March 13, 2015
PubMed
Summary
This summary is machine-generated.

Current research suggests antibiotics like macrolides, inhaled aminoglycosides, and fluoroquinolones may benefit non-cystic fibrosis (non-CF) bronchiectasis. While promising, further trials are needed to confirm their efficacy and safety for this condition.

More Related Videos

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.2K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

34.3K
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

12.2K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.3K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Non-cystic fibrosis (non-CF) bronchiectasis is a chronic respiratory condition.
  • Antibiotic use in non-CF bronchiectasis has been a focus of recent research.
  • Existing guidelines and reviews inform current treatment approaches.

Purpose of the Study:

  • To review the current literature on antibiotic treatment for non-cystic fibrosis (non-CF) bronchiectasis.
  • To summarize indications and available options for antibiotic therapy.
  • To highlight ongoing research and development in this area.

Main Methods:

  • Literature review of recent clinical articles and scientific manuscripts.
  • Synthesis of evidence on antibiotic use in non-CF bronchiectasis.
  • Identification of ongoing clinical trials.

Main Results:

  • Evidence supports the use of macrolide antibiotics, inhaled aminoglycosides, and inhaled fluoroquinolones in non-CF bronchiectasis.
  • Published data are preliminary, with ongoing Phase 3 trials.
  • No U.S. Food and Drug Administration (FDA)-approved antibiotics are currently available for bronchiectasis.

Conclusions:

  • Antibiotics show potential for treating non-CF bronchiectasis.
  • Further research is crucial to establish definitive efficacy and safety.
  • New antibiotic therapies are under development for this complex disease.